Weight-loss medicine can cut back the danger of worsening kidney operate, kidney failure and dying from kidney illness by a fifth, in accordance with a examine.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a household of medicines that assist individuals shed the kilos, handle blood sugar in sufferers with sort 2 diabetes and stop coronary heart assaults and strokes in individuals with coronary heart illness.
However whereas the advantages of the medicine for treating weight problems, sort 2 diabetes and heart problems are well-known, their potential impression on kidney well being has been much less sure.
Now the most important and most complete evaluation of GLP-1 receptor agonists on kidney outcomes suggests they might have important advantages. The findings had been printed within the Lancet Diabetes & Endocrinology journal.
Researchers carried out a meta-analysis of 11 large-scale scientific trials of weight reduction medicine involving greater than 85,000 individuals. The group included individuals with sort 2 diabetes, and folks with heart problems who had been obese or overweight however didn’t have sort 2 diabetes.
Seven completely different GLP-1 receptor agonists had been investigated among the many trials, together with semaglutide, often known as Ozempic or Wegovy, dulaglutide and liraglutide.
In contrast with placebo, GLP-1 receptor agonists lowered the danger of kidney failure by 16% and the worsening of kidney operate by 22%, researchers mentioned. The mixed discount within the danger of kidney failure, worsening kidney operate and dying on account of kidney illness was 19%.
The evaluation additionally confirmed earlier findings that weight-loss medicine shield cardiovascular well being, with a 14% discount within the danger of cardiovascular dying, non-fatal coronary heart assault and non-fatal stroke, in contrast with placebo. Dying by any trigger was 13% decrease amongst sufferers handled with GLP-1 receptor agonists.
Lead writer Prof Sunil Badve, professorial fellow on the George Institute for International Well being and UNSW Sydney, mentioned the examine expanded present data concerning the potential advantages of the medicine.
“That is the primary examine to indicate a transparent good thing about GLP-1 receptor agonists on kidney failure or end-stage kidney illness, suggesting they’ve a key position in kidney-protective and heart-protective therapy for sufferers with frequent medical circumstances like sort 2 diabetes, obese or weight problems with heart problems, or CKD [chronic kidney disease],” he mentioned.
“These outcomes are notably necessary for sufferers with continual kidney illness. It’s a progressive situation finally resulting in kidney failure requiring dialysis or kidney transplantation and is related to untimely dying, principally from coronary heart illness. It has a major impression on sufferers’ high quality of life and incurs substantial healthcare prices.”
CKD is estimated to have an effect on one in 10 individuals worldwide, equal to about 850 million individuals. It’s the tenth main reason behind dying and is projected to grow to be the fifth commonest reason behind dying by 2050.
Prof Vlado Perkovic, professorial fellow on the George Institute, provost at UNSW Sydney and senior writer on the examine, mentioned: “This analysis exhibits that GLP-1 receptor agonists might play an necessary position in addressing the international burden of non-communicable ailments.
“Our examine could have a significant impression on scientific pointers for the administration of continual kidney illness and heart problems in individuals with and with out diabetes.
“Extra work is now wanted to implement the outcomes of this examine into scientific apply and enhance entry to GLP-1 receptor agonists to individuals who will profit from them.”
Supply hyperlink
